Your browser doesn't support javascript.
loading
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Awad, Mark M; Le Bruchec, Yvan; Lu, Brian; Ye, Jason; Miller, Julie Ann; Lizotte, Patrick H; Cavanaugh, Megan E; Rode, Amanda J; Dumitru, Calin Dan; Spira, Alexander.
Affiliation
  • Awad MM; Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States.
  • Le Bruchec Y; Bristol Myers Squibb, Princeton, NJ, United States.
  • Lu B; Bristol Myers Squibb, Princeton, NJ, United States.
  • Ye J; Acetylon Pharmaceuticals, Inc, Boston, MA, United States.
  • Miller JA; Bristol Myers Squibb, Princeton, NJ, United States.
  • Lizotte PH; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
  • Cavanaugh ME; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
  • Rode AJ; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
  • Dumitru CD; Bristol Myers Squibb, Princeton, NJ, United States.
  • Spira A; Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States.
Front Oncol ; 12: 889996, 2022.
Article in En | MEDLINE | ID: mdl-35747830
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Type: Article Affiliation country: United States